Rezatapopt not checked

PMV Pharmaceuticals, Inc · PC14586

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
6 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.”In the company’s words, NCT04585750 on ClinicalTrials.gov
Tested for
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer and 24 more
Main trialPhase 1/2
“The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.”In the company’s words, NCT04585750 on ClinicalTrials.gov
Other names
PC14586

Other drugs for Advanced Solid Tumor

All 2439 drugs for Advanced Solid Tumor

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 15 Dec 2026 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1Recruiting Mar 2027 A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
Phase 1Completed 9 Jun 2022 Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers
Phase 1Completed 30 Nov 2022 AME Study of [14C]-PC14586 in Healthy Male Participants
Phase 1Completed 3 Nov 2023 A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants
Phase 1Completed 22 Oct 2024 A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Rezatapopt

Following is part of Solo: you see every change to Rezatapopt the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in